Ignite Creation Date:
2024-05-06 @ 8:16 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06318598
Status:
RECRUITING
Last Update Posted:
2024-03-19
First Post:
2024-03-08
Brief Title:
Biomarker-driven Phenotypic Dissection of Amyotrophic Lateral Sclerosis
Sponsor:
Istituto Auxologico Italiano
Organization:
Istituto Auxologico Italiano
Study Overview
Official Title:
Dissezione Fenotipica Guidata da Biomarcatori Della Sclerosi Laterale AmiotroficaBiomarker-driven Phenotypic Dissection of Amyotrophic Lateral Sclerosis
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DRIVEALS
Brief Summary:
The goal of this observational study is to understand the clinical variability in a population of ALS patients using multidimensional biomarkers The main questions it aims to answer are
Which set of biomarkers explain genotypic-phenotypic correlations in ALS
Which set of biomarkers can be used to subdivide the ALS population in homogeneous subgroups
Participants will undergo
neurological evaluation
neurophysiological evaluation
neuropsychological evaluation
whole exome sequencing
biomarker measurement in CSF and plasma
Which set of biomarkers explain genotypic-phenotypic correlations in ALS
Which set of biomarkers can be used to subdivide the ALS population in homogeneous subgroups
Participants will undergo
neurological evaluation
neurophysiological evaluation
neuropsychological evaluation
whole exome sequencing
biomarker measurement in CSF and plasma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None